The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM and Controller are not waterproof. Safe Harbor Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, and the approval of products by regulatory bodies. These forward-looking statements are based on management's current beliefs, assumptions, and estimates and are not intended to be a guarantee ...

Core Insights - Insulet reported better-than-expected fourth-quarter results driven by strong demand for its tubeless insulin pumps, forecasting 20% to 22% revenue growth for full-year 2026 in constant currency and over 25% increase in adjusted earnings per share [1] Financial Performance - Insulet's sales for the fourth quarter reached $781.8 million, exceeding analysts' estimates of $767.3 million, with total revenue jumping 31.2% to $783.8 million compared to estimates of $768.7 million [1] - On an adjusted basis, Insulet earned $1.55 per share for the quarter, surpassing estimates of $1.45 [1] Future Outlook - For the current quarter, Insulet forecasts revenue growth of 25% to 27% in constant currency [1] - The company announced a $350 million increase to its share repurchase authorization, planning to deploy approximately $300 million in buybacks during the first quarter of 2026, which analysts view as a bullish signal [1] Product Demand - Insulet's sales surge is attributed to broader regulatory approvals for its Omnipod 5 automated insulin delivery system, now cleared for use in both type 1 and type 2 diabetes patients in the U.S. [1] - The demand for Insulet's products aligns with similar trends observed in the market, as its larger peer Dexcom also reported robust demand for continuous glucose monitoring systems [1]

Acton, Massachusetts-based Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. Valued at a market capitalization of $17.1 billion, the company offers the Omnipod platform, comprising the Omnipod 5 automated insulin delivery system and the Omnipod DASH insulin management system. The company's shares have underperformed the broader market over the past year and in 2026. PODD stock has decl ...

Financial Performance - Fourth Quarter 2025 revenue reached $783.8 million, a 31.2% increase year-over-year, exceeding guidance of 25% to 28%[4] - Total Omnipod revenue for the year was $2.7 billion, up 31.6%, with U.S. revenue growing 27.2% to $1.9 billion and international revenue increasing 44.1% to $754.3 million[4] - Gross margin improved to 72.5% in Q4 2025, up 40 basis points from the prior year, while full year gross margin was 71.6%, up 180 basis points[4] - Net income for Q4 2025 was $101.6 million, or $1.44 per diluted share, compared to $100.7 million, or $1.39 per diluted share, in the prior year[4] - Adjusted net income for the full year 2025 was $354.4 million, a 53.8% increase compared to the prior year[4] - Net income for the year 2025 was $247.1 million, compared to $418.3 million in 2024, showing a decrease due to various factors including tax expenses[24] - The diluted earnings per share for Q4 2025 was $1.44, consistent with Q4 2024, reflecting stable earnings despite revenue growth[24] - Net income for 2025 was $101.6 million, representing 13.0% of revenue, compared to $100.7 million and 16.9% in 2024[34] - Adjusted EBITDA for 2025 reached $194.0 million, accounting for 24.8% of revenue, up from $151.1 million and 25.3% in 2024[34] Market Growth - The company achieved over 600,000 estimated active Omnipod users globally by the end of 2025, reflecting strong adoption rates[8] - Insulet ranked 1 in new customer starts in both the U.S. and Europe in 2025, indicating strong market demand for its products[8] - The company reported a 28.0% revenue growth in the U.S. market for Q4 2025, with revenues of $567.8 million compared to $443.6 million in Q4 2024[29] - International revenue grew by 50.7% in Q4 2025, reaching $214.0 million, compared to $142.1 million in Q4 2024[29] - The company achieved a constant currency revenue growth of 29.0% for the year ended December 31, 2025, highlighting strong operational performance[29] Financial Health - Total assets as of December 31, 2025, were $3,190.4 million, up from $3,087.7 million in 2024, indicating a solid asset base[27] - Total liabilities decreased to $1,675.2 million in 2025 from $1,876.1 million in 2024, indicating improved financial health[27] - Free cash flow increased to $377.7 million in 2025, compared to $305.3 million in 2024, reflecting a growth of 23.7%[36] - The company reported a net cash provided by operating activities of $569.3 million in 2025, up from $430.2 million in 2024[36] Future Guidance - For Q1 2026, Insulet expects total revenue growth of 25% to 27%, with U.S. growth projected at 24% to 26% and international growth at 37% to 39%[9] - Revenue guidance for 2026 projects total growth of 21% - 23%, with U.S. growth expected at 20% - 22% and international growth at 27% - 29%[38] - For the first quarter of 2026, total revenue growth is anticipated to be 27% - 29%, with U.S. growth at 24% - 26% and international growth at 48% - 50%[38] - The total Omnipod Products revenue growth for 2026 is expected to be 22% - 24%, with a constant currency growth of 21% - 23%[38] - The company anticipates a significant decline in Drug Delivery revenue, projected at approximately -50% for 2026[38] Investment and Innovation - Research and development expenses increased to $301.1 million in 2025 from $219.6 million in 2024, indicating a focus on innovation[24] - Insulet received FDA clearance for significant enhancements to the Omnipod 5 algorithm, improving customization and glucose management capabilities[8] - The company plans to allocate approximately $300 million towards share repurchases in Q1 2026, reflecting strong financial flexibility[6] - Capital expenditures for 2025 were $191.6 million, an increase from $124.9 million in 2024[36] - The adjusted EBITDA for the year ended December 31, 2025, includes a reversal of stock-based compensation expense totaling $11.7 million related to the former CFO and CEO[34]

Investor presentation February 18, 2026 Chloe Podder since 2021 The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM and Controller are not waterproof. Safe Harbor Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, and the approval of products by regulatory bodies. These forward-looking statements are based on management's current beliefs, a ...

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that humanoid robots could create a market worth $250 trillion by 2040, representing a major shift in the global economy driven by AI innovation [2] - Major consulting firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, reinforcing the optimistic outlook on the technology's economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is believed to be redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, suggesting that it could be a significant investment opportunity [4] - Prominent figures in technology and finance, including Bill Gates and Warren Buffett, recognize AI as a major technological advancement with the potential for substantial social benefits [8] Market Dynamics - The AI ecosystem is expected to reshape how businesses, governments, and consumers operate globally, indicating a broad impact across various sectors [2] - The competitive landscape includes major players like Tesla, Nvidia, Alphabet, and Microsoft, but there is a belief that a smaller company may offer even greater opportunities [6] - The potential for AI to improve sectors such as healthcare and education is highlighted, suggesting diverse applications and benefits from the technology [8]

Core Viewpoint - Insulet (PODD) is expected to report a quarterly earnings per share (EPS) of $1.48, marking a 28.7% increase year-over-year, with revenues projected at $767.33 million, reflecting a 28.4% year-over-year growth [1]. Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating that analysts have not revised their initial projections [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts predict 'Revenue- Total Omnipod' to be $765.48 million, indicating a year-over-year increase of 30.7% [5]. - The 'Revenue- Drug Delivery' is estimated to reach $0.97 million, which represents a significant decline of 91.8% from the previous year [5]. - The consensus for 'Revenue- International Omnipod' is set at $209.64 million, showing a year-over-year increase of 47.6% [5]. - 'Revenue- U.S. Omnipod' is expected to be $555.84 million, reflecting a year-over-year growth of 25.3% [6]. Stock Performance - Over the past month, Insulet shares have decreased by 11.3%, while the Zacks S&P 500 composite has only declined by 0.3% [6]. - Insulet currently holds a Zacks Rank of 4 (Sell), suggesting it may underperform the overall market in the near future [6].

Group 1 - Insulet Corporation (NASDAQ:PODD) is recognized as one of the top 12 Medical Devices stocks favored by hedge funds, with a highly bullish consensus view from analysts [1] - The stock has received coverage from 18 analysts, resulting in 16 Buy ratings, 1 Hold rating, and only 1 Sell rating, indicating strong market confidence [1] - The consensus 1-year median price target for Insulet is $369.59, suggesting an upside potential of over 43% from its current level [1] Group 2 - Analyst David Roman from Goldman Sachs reaffirmed a Buy rating for Insulet, adjusting the price target from $388 to $365, while still projecting over 41% upside potential [2] - Roman noted that share price movements in 2025 diverged from company fundamentals, but expects valuations to align closely with organic growth prospects in the coming year [2] Group 3 - Insulet Corporation specializes in manufacturing and selling insulin management systems, particularly through its Omnipod platform, which includes a disposable tubeless pump designed for insulin-dependent diabetes [3] - The company's strategy focuses on high-volume automated manufacturing in the US and Malaysia, along with contract manufacturing in China [3]

Upgrades - CoStar Group (CSGP) upgraded to Buy from Neutral with an $80 price target due to low expectations, past peak investment, and momentum from Homes.com, along with an anticipated AI-driven product update [2] - Teleflex (TFX) upgraded to Buy from Hold with a $138 price target as the company plans to sell its acute care, interventional urology, and manufacturing businesses for $2 billion, expecting significant earnings accretion from share repurchases and debt repayment by 2027 [3] - CoreWeave (CRWV) upgraded to Buy from Hold with a $140 price target, with a solid medium-term outlook ahead of the Q4 report [3] - Affirm (AFRM) upgraded to Buy from Hold with a $100 price target after submitting an application to establish Affirm Bank, which could be a game-changer [4] - Target (TGT) upgraded to Peer Perform from Underperform without a price target, with a wide margin of safety despite reduced estimates due to the company's owned real estate [4] Downgrades - Procter & Gamble (PG) downgraded to Hold from Buy with a price target of $156, up from $150, as the pace of recovery is expected to drag [5] - Stryker (SYK) downgraded to Hold from Buy with a $387 price target following a transfer in analyst coverage, with a well-understood valuation reflecting a "beat/raise precedent" [5] - Insulet (PODD) downgraded to Hold from Buy with a $294 price target after a transfer in analyst coverage, noting that competitive advantages may narrow [5] - Matador (MTDR) downgraded to Equal Weight from Overweight with a price target of $47, down from $61, due to stock valuation incorporating structural considerations and recent productivity variability [5] - SkyWater Technology (SKYT) downgraded to Hold from Buy with a price target of $35, up from $24, after agreeing to be acquired by IonQ for $35 per share or $1.88 billion [5]

Core Insights - Insulet Corporation specializes in innovative diabetes management solutions, particularly known for its Omnipod Insulin Management System, a tubeless, wearable pump that delivers continuous insulin for up to three days [1][2] Company Overview - Insulet is headquartered in Acton, Massachusetts, and operates globally, leveraging advanced manufacturing for scalable production and research and development [2] - The company has a market capitalization of $20 billion [2] Financial Performance - Insulet is expected to report a profit of $1.48 per share for Q4 fiscal 2025, representing a 28.7% year-over-year growth [4] - For the full fiscal year 2025, analysts anticipate Insulet's diluted EPS to grow by 50.9% to $4.89, followed by a 26.4% increase to $6.18 in fiscal 2026 [4] Stock Performance - Over the past 52 weeks, Insulet's stock has gained 3.2%, while the S&P 500 Index has increased by 13.7% during the same period, indicating underperformance [5] - The stock gained 2.9% intraday on November 6, 2025, following better-than-expected third-quarter results, with revenue increasing by 29.9% year-over-year to $706.30 million [6] - Insulet's total Omnipod revenue rose by 31% to $699.20 million, and its non-GAAP EPS increased by 37.8% to $1.24 [6] Guidance - Based on recent growth, the company raised its fiscal 2025 revenue guidance from a growth range of 24%-27% to 28%-29% [6]